Company intelligence / Profile preview
China Biologic Products Holdings
Beijing, Beijing, Chinachinabiologic.com ↗
- Ownership
- Private
- Employees
- ~2246
- Development stage
- Other
01
Overview
China Biologic Products focuses on commercialized plasma-derived biologics such as human albumin, immunoglobulins, and coagulation factor products, with strong sales growth and leadership in China’s plasma sector through integrated operations and regulatory compliance
- Therapeutic areas
- CardiovascularHematologyImmunologyInfectious Diseases
- Modalities
- BiologicRecombinant proteinProteinPlasma-derived therapy
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Acquisition/ownership consortium included Centurium Capital, CITIC Capital, Hillhouse Capital, Temasek Holdings, management group
Beyond the preview
Go deeper on China Biologic Products Holdings.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on China Biologic Products Holdings.